Ruxolitinib: A steroid sparing agent in chronic graft-versus-host disease

Hanna Jean Khoury; Amelia A. Langston; Vamsi Kota; Jennifer A. Wilkinson; Iskra Pusic; Anand Jillella; Stephanie Bauer; Audrey S. Kim; Danielle Roberts; Zaid Al-Kadhimi; Imre Bodo; Elliott Winton; Martha Arellano; John F. Dipersio

doi:10.1038/s41409-017-0081-5

Ruxolitinib: A steroid sparing agent in chronic graft-versus-host disease

Hanna Jean Khoury
, Amelia A. Langston
, Vamsi Kota
, Jennifer A. Wilkinson
, Iskra Pusic
, Anand Jillella
, Stephanie Bauer
, Audrey S. Kim
, Danielle Roberts
, Zaid Al-Kadhimi
, Imre Bodo
, Elliott Winton
, Martha Arellano
, John F. Dipersio

Pulmonary Disease

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Abstract

Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7%), cutaneous (82/0%), hepatic (71/28%), gastro-intestinal (75/17%), musculoskeletal (33/67%), pulmonary (0/80%), scleroderma (0/75%), vaginal (0/75%), and ocular (0/100%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68%) or reduction of steroids to physiologic doses (21%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.

Original language	English (US)
Pages (from-to)	826-831
Number of pages	6
Journal	Bone marrow transplantation
Volume	53
Issue number	7
DOIs	https://doi.org/10.1038/s41409-017-0081-5
State	Published - Jul 1 2018

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/s41409-017-0081-5

Cite this

@article{909ae5bfcc704612821bba4e67e38315,

title = "Ruxolitinib: A steroid sparing agent in chronic graft-versus-host disease",

abstract = "Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7\%), cutaneous (82/0\%), hepatic (71/28\%), gastro-intestinal (75/17\%), musculoskeletal (33/67\%), pulmonary (0/80\%), scleroderma (0/75\%), vaginal (0/75\%), and ocular (0/100\%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68\%) or reduction of steroids to physiologic doses (21\%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.",

author = "Khoury, \{Hanna Jean\} and Langston, \{Amelia A.\} and Vamsi Kota and Wilkinson, \{Jennifer A.\} and Iskra Pusic and Anand Jillella and Stephanie Bauer and Kim, \{Audrey S.\} and Danielle Roberts and Zaid Al-Kadhimi and Imre Bodo and Elliott Winton and Martha Arellano and Dipersio, \{John F.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Macmillan Publishers Limited, part of Springer Nature.",

year = "2018",

month = jul,

day = "1",

doi = "10.1038/s41409-017-0081-5",

language = "English (US)",

volume = "53",

pages = "826--831",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "7",

}

TY - JOUR

T1 - Ruxolitinib

T2 - A steroid sparing agent in chronic graft-versus-host disease

AU - Khoury, Hanna Jean

AU - Langston, Amelia A.

AU - Kota, Vamsi

AU - Wilkinson, Jennifer A.

AU - Pusic, Iskra

AU - Jillella, Anand

AU - Bauer, Stephanie

AU - Kim, Audrey S.

AU - Roberts, Danielle

AU - Al-Kadhimi, Zaid

AU - Bodo, Imre

AU - Winton, Elliott

AU - Arellano, Martha

AU - Dipersio, John F.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7%), cutaneous (82/0%), hepatic (71/28%), gastro-intestinal (75/17%), musculoskeletal (33/67%), pulmonary (0/80%), scleroderma (0/75%), vaginal (0/75%), and ocular (0/100%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68%) or reduction of steroids to physiologic doses (21%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.

AB - Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7%), cutaneous (82/0%), hepatic (71/28%), gastro-intestinal (75/17%), musculoskeletal (33/67%), pulmonary (0/80%), scleroderma (0/75%), vaginal (0/75%), and ocular (0/100%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68%) or reduction of steroids to physiologic doses (21%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.

UR - https://www.scopus.com/pages/publications/85040911317

UR - https://www.scopus.com/pages/publications/85040911317#tab=citedBy

U2 - 10.1038/s41409-017-0081-5

DO - 10.1038/s41409-017-0081-5

M3 - Article

C2 - 29367708

AN - SCOPUS:85040911317

SN - 0268-3369

VL - 53

SP - 826

EP - 831

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 7

ER -

Ruxolitinib: A steroid sparing agent in chronic graft-versus-host disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this